Maze Therapeutics (NASDAQ:MAZE) Shares Down 4% - Here's Why

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) was down 4% during trading on Wednesday . The stock traded as low as $11.61 and last traded at $11.90. Approximately 13,428 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 221,583 shares. The stock had previously closed at $12.39.

Analysts Set New Price Targets

Several research analysts have commented on MAZE shares. Leerink Partners started coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They issued an "outperform" rating and a $28.00 price objective for the company. Leerink Partnrs upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price target for the company. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Finally, Guggenheim reiterated a "buy" rating and issued a $19.00 price target on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Maze Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $25.67.

Maze Therapeutics Trading Down 9.5%

The firm has a 50 day moving average price of $10.34.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Institutional Trading of Maze Therapeutics

Several institutional investors have recently bought and sold shares of the company. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $66,874,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $45,460,000. ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $45,362,000. Matrix Capital Management Company LP bought a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $27,373,000. Finally, Alphabet Inc. bought a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.